



**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

**Equivalent of Form PTO/SB/08A (07-05)**

Approved for use through 07/31/2006.

**U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**


<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/069,626
				Filing Date	July 25, 2002
				First Named Inventor	Cynthia GREEN
				Art Unit	1644
				Examiner Name	Ilia I. Ouspenski
Sheet	1	of	1	Attorney Docket Number	2159.0960004/EKS/PAC

Examiner Signature	/Ilia Ouspenski/	Date Considered	10/05/2006
-----------------------	------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RENEWAL FORM FOR FORM 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

Sheet

1 of 2

*Complete if Known*

Application Number	10/069,626
Filing Date	July 25, 2002
First Named Inventor	Cynthia GREEN
Art Unit	1644
Examiner Name	Ilia I. Ouspenski

Attorney Docket Number 2159.0960004/EKS/PAC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
IO	NPL1	Abbas, A.K. and Sharpe, A.H., "T-cell stimulation: an abundance of B7s," <i>Nat. Med.</i> 5:1345-1346, Nature America, Inc. (December 1999)	
	NPL2	Branch, A.D., "A good antisense molecule is hard to find," <i>Trends Biochem. Sci.</i> 23:45-50, Elsevier Science Ltd. (February 1998)	
	NPL3	Chapoval, A.I., et al., "B7-H3: A costimulatory molecule for T cell activation and IFN-γ production," <i>Nat. Immunol.</i> 2:269-274, Nature America, Inc. (March 2001)	
	NPL4	Dong, H., et al., "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," <i>Nat. Med.</i> 5:1365-1369, Nature America, Inc. (December 1999)	
	NPL5	Freeman, G.J., et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," <i>J. Exp. Med.</i> 174:625-631, The Rockefeller University Press (1991)	
	NPL6	Greenfield, E.A., et al., "CD28/B7 Costimulation: A Review," <i>Crit. Rev. Immunol.</i> 18:389-418, Begell House, Inc. (1998)	
	NPL7	Janeway, C.A., et al., eds., "Chapter 7. The Adaptive Immune Response," in: <i>Immunobiology - The Immune System in Health and Disease</i> , 3 <sup>rd</sup> Ed., Garland Publishing Inc., New York, NY, pp. 7:1-7:44 (1997)	
	NPL8	Ling, V., et al., "Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor," <i>J. Immunol.</i> 164:1653-1657, The American Association of Immunologists (February 2000)	
↓	NPL9	Linsley, P.S., et al., "Extending the B7 (CD80) gene family," <i>Prot. Sci.</i> 3:1341-1343, Cambridge University Press (1994)	
IO	NPL10	Mountain, A., "Gene therapy: the first decade," <i>Trends Biotechnol.</i> 18:119-128, Elsevier Science Ltd. (March 2000)	

Ilia Ouspenski


10/05/2006

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperless Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for FORM 147/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/069,626
		Filing Date	July 25, 2002
		First Named Inventor	Cynthia GREEN
		Art Unit	1644
		Examiner Name	Ilia I. Ouspenski
Sheet	2	of	2
		Attorney Docket Number	
		2159.0960004/EKS/PAC	

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	
IO	NPL11	Nishimura, Y., et al., "Molecular cloning of the cDNAs encoding the feline B-lymphocyte activation antigen B7-1 (CD90) and B7-2 (CD86) homologues which interact with human CTLA4-Ig," <i>Eur. J. Immunogen.</i> 27:427-430, Blackwell Science Ltd. (December 2000)	
	NPL12	Selvakumar, A., et al., "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," <i>Immunogen.</i> 36:175-181, Springer International (1992)	
	NPL13	Skolnick, J. and Fetrow, J.S., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18:34-39, Elsevier Science Ltd. (January 2000)	
	NPL14	Swallow, M.M., et al., "B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNF $\alpha$ ," <i>Immunity</i> 11:423-432, Cell Press (October 1999)	
	NPL15	Thompson, C.B., "Distinct Roles for the Costimulatory Ligands B7-1 and B7-2 in T Helper Cell Differentiation?," <i>Cell</i> 81:979-982, Cell Press (1995)	
	NPL16	Voet, S. and Voet, J.G., "3. Chemical Evolution," in: <i>Biochemistry</i> , John Wiley & Sons, New York, NY, pp. 126-230 (1990)	
	NPL17	Zhang, D. and Johnson, R.P., "Molecular Cloning and Comparative Analysis of the Rhesus Macaque Costimulatory Molecules CD80 (B7-1) and CD86 (B7-2)," <i>Cellul. Immunol.</i> 177:9-17, Academic Press (1997)	
↓			
IO			

506914v1

/Ilia Ouspenski/

10/05/2006

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.